5-MeO-DALT

5-MeO-DALT

5-MeO-DALT

Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.

Description

5-MeO-DALT

Also known as:

  • 1H-Indole-3-ethanamine, 5-methoxy-N,N-di-2-propen-1-yl-[ACD/Index Name]
  • 5-MeO-DALT
  • 5-MeO-DALT solution
  • MFCD11655942[MDL number]
  • n,n-diallyl-5-methoxytryptamine
  • N-Allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-2-propen-1-amin[German][ACD/IUPAC Name]
  • N-Allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-2-propen-1-amine[ACD/IUPAC Name]
  • N-Allyl-N-[2-(5-méthoxy-1H-indol-3-yl)éthyl]-2-propén-1-amine[French][ACD/IUPAC Name]
  • N-Allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine
  • V25VK0QTAA
  • [928822-98-4]
  • 10.1016/j.bmcl.2013.03.066
  • 5-?METHOXY-?N,?N-?DI-?2-?PROPEN-?1-?YL-?1H-?INDOLE-?3-?ETHANAMINE
  • 5-MeO-DALT (5-Methoxy-N,N-diallyltryptamine)
  • 5-MeO-DALT (5-Methoxy-N,N-diallyltryptamine) 1.0 mg/ml in Acetonitrile
  • 5-methoxy DALT
  • 5-methoxy-N,N-di-2-propen-1-yl-1H-indole-3-ethanamine
  • 5-Methoxy-N,N-diallyl-1H-indole-3-ethanamine
  • 5-Methoxy-N,N-diallyltryptamine
  • '928822-98-4
  • BR-27697
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-enyl-2-propen-1-amine
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-enylprop-2-en-1-amine
  • N-2-(5-methoxy-1H-indole-3-yl)ethyl-N-(prop-2-en-1-yl)prop-2-en-1-amine[ACD/IUPAC Name]
  • N-Allyl-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)prop-2-en-1-amine
  • QA-3151
  • UNII:V25VK0QTAA
  • UNII-V25VK0QTAA

A strange drug with an unknown mechanism of action. Some psychedelic effects alongside some effects non-characteristic of psychedelics like appetite enhancement. Reported as having rapid, intense and short acting entheogenic effects.

Summary

It is structurally related to tryptamines like 5-MeO-DiPT and DALT, although it is reported to produce distinct effects. 5-MeO-DALT was first synthesized by Alexander Shulgin, who sent the first material regarding the synthesis and effects to a researcher in May 2004. This material was subsequently circulated online and the compound soon appeared on the online research chemical market.

In August 2004, the synthesis and effects of 5-MeO-DALT were officially published by Erowid. Reports linked to the detection of 5-MeO-DALT began to surface in 2007. Anecdotal reports characterize the effects of this substance as being primarily physical in nature, lacking the characteristic visual distortions or perceptual depth of most psychedelics.

Its headspace has been described as “shallow,” albeit suited for sexual contexts due to its potent stimulating and libidinous effects. It is also reported to produce more uncomfortable cardiovascular effects such as increased blood pressure and heart rate relative to other psychedelics. This has raised questions about possible toxicity associated with long-term or heavy uses.

Very limited data exists about the pharmacological properties, metabolism, and toxicity of 5-MeO-DALT, and it has a very short history of human use. It is highly advised to use harm reduction practices if using this substance.

History

Chemistry

5-MeO-DALT

5-MeO-DALT

It contains two allyl groups bound to the amino group and a 5-methoxy group bound to the indole ring of tryptamine.

It is a structural analog of DALT and 5-MeO-DiPT.

5-MeO-DALT is an off-white powder at room temperature.

Common Name5-MeO-DALT
Systematic name5-MeO-DALT
FormulaC_{17}H_{22}N_{2}O
SMILESCOc1ccc2c(c1)c(c[nH]2)CCN(CC=C)CC=C
Std. InChiInChI=1S/C17H22N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h4-7,12-13,18H,1-2,8-11H2,3H3
Std. InChiKeyHGRHWEAUHXYNNP-UHFFFAOYSA-N
Avg. Mass270.3694 Da
Molecular Weight270.3694
Monoisotopic Mass270.173218 Da
Nominal Mass270
ChemSpider ID21106245

Subscribe for the latest updates

Dosing Guide

Oral
Threshold4-5mg
Light5-12mg
Common12-20mg
Strong20+mg
Vaporized
Light2-5mg
Common5-15mg
Strong15+mg

Duration

Oral
Onsetminutes
Duration2-4 hours
After-effects1-2 hours

Interactions and Synergies

There are no existing interaction or synergy data for this drug.

General Information

Experiences
Oral
Vaporization
Come up
Dosage
EffectsEuphoria, empathy, insight, brightened colour, Closed/Open eye visuals, enhanced tactile sensation, mental/physical stimulation, decreased appetite, pupil dilation, restlessness, change in perception, ego softening, sweating/chills, muscle tension, confusion, insomnia.
After Effects
AvoidMAOI's.
Warning
Risks
Test Kits
Marguis Test Result
Tolerance
Detection
Half-life
Advice
Note
Note 2:
Note 3:

Effects

Pharmacological Effects

5-MeO-DALT acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from its efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience remains the subject of ongoing scientific investigation.

Subjective Effects

Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical Effects

Psychological Effects

The headspace of 5-MeO-DALT is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high doses.

Visual Effects

Enhancements

Distortions

Geometry

The visual geometry that is present throughout the experience can be described as more similar in appearance to that of AMT than that of LSD, 2C-B or 2C-I. It can be comprehensively described as unstructured in its organization, synthetic in geometric style, intricate in complexity, small in size, slow and smooth in motion, colourful in scheme, glossy in colour, equally blurred and sharp in its edges and equally rounded and angular in its corners. It possesses a synthetic feel that is less impressive than most of the "classical" psychedelics at any level. It has yet to be confirmed whether this compound results in either level 8A or level 8B geometry at heavy doses.

Auditory Effects

Sensory Effects

Transpersonal Effects

Legal Status

  • Austria: Since January 1, 2012, 5-MeO-DALT is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
  • China: 5-MeO-DALT is a controlled substance in China as of October 2015.
  • Germany: 5-MeO-DALT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
  • Japan: 5-MeO-DALT became a controlled substance in Japan in April 2007 due to an amendment to the Pharmaceutical Affairs Law.
  • Sweden: 5-MeO-DALT is a Schedule I substance in Sweden as of May 1, 2012. It was published by Medical Products Agency in their regulation LVFS 2012:6.
  • United Kingdom: 5-MeO-DALT is a Class A drug in the UK as it is an ether of the drug 5-HO-DALT, which is a Class A drug as a result of the tryptamine catch-all clause.
  • United States: 5-MeO-DALT is unscheduled in the United States. It may be considered an analogue of 5-MeO-DiPT, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
    • Florida: 5-MeO-DALT is a Schedule I controlled substance in the state of Florida, making it illegal to buy, sell, or possess.

  • References

    1. http://www.vice.com/en_uk/read/the-last-interview-with-alexander-shulgin-423-v17n5
    2. Brandt, S. D., Kavanagh, P. V., Dowling, G., Talbot, B., Westphal, F., Meyer, M. R., ... & Halberstadt, A. L. (2017). Analytical characterization of N, N‐diallyltryptamine (DALT) and 16 ring‐substituted derivatives. Drug Testing and Analysis, 9(1), 115-126. https://doi.org/10.1002/dta.1974
    3. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
    4. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
    5. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    6. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    7. "厚生労働省:平成18年度無承認無許可医薬品等買上調査の結果について". Retrieved 2012-06-26.
    8. http://www.lakemedelsverket.se/upload/lvfs/LVFS_2012_6.pdf
    9. Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/3
    10. Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e
    11. Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL

    Resources

    1. 1717 CheMall HE056231
    2. 1717 CheMall HE226934
    3. 4C Pharma Scientific 4CH-007986
    4. A&J Pharmtech AJ-102842
    5. abcr AB436758
    6. ABI Chemicals AC2A00UY2
    7. Accel Pharmtech FB5161
    8. AChemo AC-78679
    9. Activate Scientific AS33478
    10. AEchem Scientific AE1-011687
    11. AK Scientific W9569
    12. AKos AKOS005145816
    13. Amadis Chemical A844374
    14. American Custom Chemicals Corp CHM0393660
    15. Angene AGN-PC-04XNH3
    16. Anward ANW-49667
    17. Apexmol AM20041417
    18. Ark Pharm, Inc. AK-27697
    19. Aurora Fine Chemicals A08.467.693
    20. Aurora Fine Chemicals K07.021.381
    21. BePharm 5-Methoxy-N,N-diallyl-1H-indole-3-ethanamine
    22. BePharm B158402
    23. BerrChem BR-27697
    24. Bide Pharmatech BD158402
    25. BindingDB 50435344
    26. BOC Sciences 928822-98-4
    27. Cambridge Chem B158402
    28. Cayman Chemical 10729
    29. Cayman Chemical 10729.0
    30. ChEMBL CHEMBL2391541
    31. ChemIDplus 928822984
    32. Chemspace CSC016987452
    33. EPA DSSTox DTXCID00161660
    34. Erowid 5-MeO-DALT
    35. FDA UNII - NLM UNII: V25VK0QTAA
    36. FDA UNII - NLM V25VK0QTAA
    37. Finetech Industry FT-0650146
    38. iChemical EBD31816
    39. LabNetwork
    40. LabNetwork LN00174933
    41. Letopharm LT0312231
    42. LGC Standards LGCAMP1275.07-11
    43. LGC Standards LGCFOR1275.07
    44. Manchester Organics U45857
    45. Matrix Scientific 073209
    46. Mcule MCULE-1523560051
    47. MolCore CS12230
    48. Molepedia M10082782P
    49. Molport MolPort-009-197-823
    50. MuseChem R052794
    51. Novochemy NC-6642
    52. OXchem
    53. OXchem AX8158402
    54. Rosewachem RW094879
    55. Ryan Scientific 047-92157
    56. Ryan Scientific 048-19090
    57. Ryan Scientific 077-47528
    58. Sigma-Aldrich CERILLIAN-M-165
    59. Sigma-Aldrich M-165
    60. Springer Nature A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 ??-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches
    61. Springer Nature Identification of a new synthetic cannabinoid in a herbal mixture: 1-butyl-3-(2-methoxybenzoyl)indole
    62. Springer Nature Simultaneous determination of tryptamine analogues in designer drugs using gas chromatographyu2013mass spectrometry and liquid chromatographyu2013tandem mass spectrometry
    63. Springer Nature Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013
    64. Tractus Company Limited
    65. VulcanChem VC247609
    66. Wikidata Q9134216
    67. Wikipedia 5-MeO-DALT
    68. Wonderchem WD04E4B

    Sources

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.